1 Introduction (Page No. – 20)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency Used for the Study
1.5 Major Market Stakeholders
2 Research Methodology (Page No. – 23)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Secondary Sources
2.1.2 Primary Data
2.2 Market Estimation Methodology
2.2.1 End User-Based Market Estimation
2.2.2 Revenue Mapping-Based Market Estimation
2.2.3 Primary Research Validation
2.3 Data Triangulation
2.4 Research Assumptions
2.5 Research Limitations
3 Executive Summary (Page No. – 31)
4 Premium Insights (Page No. – 35)
4.1 Market Overview
4.2 Neurodiagnostics Market, By Product, 2019 Vs. 2024
4.3 Market Share, By End User and Region (2019)
4.4 Market, By Condition, 2019 Vs. 2024 (USD Million)
4.5 Market, By Country
5 Market Overview (Page No. – 40)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Prevalence of Neurological Diseases & Disorders
5.2.1.2 Technological Advancements
5.2.1.3 Growing Patient Emphasis on Effective and Early Disease Diagnosis
5.2.1.4 Increasing Number of Diagnostic Centers & Hospitals
5.2.1.5 Advances in Genomics and Proteomics for the Diagnosis of Neurodegenerative Disorders
5.2.2 Restraints
5.2.2.1 High Cost of Neurodiagnostic Devices
5.2.2.2 Growing Adoption of Refurbished Neurodiagnostic Systems
5.2.3 Opportunities
5.2.3.1 Increasing Application in Clinical Trials
5.2.3.2 Emerging Markets
5.2.4 Challenges
5.2.4.1 Dearth of Skilled Surgeons
6 Neurodiagnostics Market, By Product (Page No. – 46)
6.1 Introduction
6.2 Diagnostic Imaging Systems
6.2.1 Growing Number of Diagnostic Laboratories & Imaging Centers to Drive the Adoption of Diagnostic Imaging Systems
6.2.1.1 MRI Systems
6.2.1.2 EEG Systems
6.2.1.3 CT Scanners
6.2.1.4 PET Scanners
6.2.1.5 EMG Devices
6.2.1.6 Ultrasound Imaging Systems
6.2.1.7 MEG Devices
6.2.1.8 Angiography Systems
6.2.1.9 Other Diagnostic Imaging Systems
6.3 Clinical Diagnostic Instruments
6.3.1 Increasing Public-Private Investments are Supporting the Growth of This Market Segment
6.3.1.1 PCR Instruments
6.3.1.2 NGS Instruments
6.3.1.3 Sanger Sequencers
6.3.1.4 Other Clinical Diagnostic Instruments
6.4 Reagents & Consumables
6.4.1 High Consumption of Reagents in Various Routine Assays & Techniques is Driving the Growth of This Segment
6.4.1.1 Media & Sera
6.4.1.2 Antibodies
6.4.1.3 Buffers
6.4.1.4 Solvents
6.4.1.5 Enzymes, Proteins, & Peptides
6.4.1.6 Probes
6.4.1.7 Other Reagents & Consumables
7 Neurodiagnostics Market, By Condition (Page No. – 87)
7.1 Introduction
7.2 Neurodegenerative Diseases
7.2.1 Growing Number of Neurological Examinations is Supporting the Growth of This Segment
7.3 Stroke
7.3.1 Growing Awareness About Strokes & Its Treatment Options in the Market are Supporting Market Growth
7.4 Epilepsy
7.4.1 Favorable Government Initiatives Have Resulted in the Increased Adoption of Neurodiagnostic Products
7.5 Headache Disorders
7.5.1 Increasing Incidence of Migraines & Tension Headaches to Support Market Growth
7.6 Sleep Disorders
7.6.1 Increasing Stress & Unhealthy Lifestyles are Supporting the Growth of This Market Segment
8 Neurodiagnostics Market, By End User (Page No. – 95)
8.1 Introduction
8.2 Hospitals & Surgical Centers
8.2.1 Hospitals & Surgical Centers are the Major End Users of Neurodiagnostic Devices Owing to Their High Purchasing Power to Buy Expensive Equipment
8.3 Diagnostic Laboratories & Imaging Centers
8.3.1 Growing Number of Private Imaging Centers Supports the Growth of This End-User Segment
8.4 Neurology Centers
8.4.1 Lower Costs and Shorter Waiting Periods Compared to Hospitals to Drive Market Growth
8.5 Ambulatory Care Centers
8.5.1 High-Quality and Lower-Cost Services Offered By Ambulatory Care Centers to Drive Market Growth
8.6 Research Laboratories & Academic Institutes
8.6.1 Budgetary Limitations Faced By Small Research Laboratories & Academic Institutes Will Restrain Market Growth
9 Neurodiagnostics Market, By Region (Page No. – 102)
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 US Dominates the Market Due to the Increased Adoption of High-End Neurodiagnostic Systems
9.2.2 Canada
9.2.2.1 Favorable Environment for R&D in the Field of Neurosciences is Driving Market Growth
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany Commands the Largest Share of the Neurodiagnostics Market in Europe
9.3.2 UK
9.3.2.1 Market Growth in the UK is Mainly Driven By the Increasing Incidence of Neurodegenerative Diseases
9.3.3 France
9.3.3.1 Increasing Healthcare Expenditure Coupled With the High-End Medical Infrastructure Will Drive Demand for Neurodiagnostic Devices
9.3.4 Italy
9.3.4.1 Ongoing Economic Crisis in the Country and Rising Government Pressure to Reduce Healthcare Costs May Slow Market Growth
9.3.5 Spain
9.3.5.1 Increased Cost Burden on the State-Run Health Insurance System Will Hinder Market Growth
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.1.1 Favorable Reimbursement and Growing Neurological Disorder Patients Have Propelled Market Growth in Japan
9.4.2 China
9.4.2.1 Government Initiatives to Modernize Healthcare Facilities and the Rising Geriatric Population Will Drive Market Growth
9.4.3 India
9.4.3.1 Low Entry Barriers Have Made India a Prominent Market to Invest In
9.4.4 Australia
9.4.4.1 Technology Advancements and Improving Healthcare Infrastructure Will Drive the Market in Australia
9.4.5 South Korea
9.4.5.1 Rising Healthcare Spending and Medical Coverage for Neurological Disease Treatment Will Propel the Market Growth
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.1.1 Inadequate Accessibility to Healthcare has Driven the Government to Undertake Corrective Measures
9.5.2 Mexico
9.5.2.1 Mexico is a Prominent Medical Tourism Hub for US Patients
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 Infrastructural Development and Growing Healthcare Expenditure Will Contribute to Market Growth in the MEA
10 Competitive Landscape (Page No. – 165)
10.1 Overview
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Key Product Launches
10.3.2 Key Expansions
10.3.3 Key Acquisitions
10.3.4 Key Partnerships, Agreements, and Collaborations
10.4 Competitive Leadership Mapping
10.4.1 Visionary Leaders
10.4.2 Innovators
10.4.3 Dynamic Differentiators
10.4.4 Emerging Companies
11 Company Profiles (Page No. – 172)
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 GE Healthcare
11.2 Philips Healthcare
11.3 Siemens Healthineers
11.4 Hitachi, Ltd.
11.5 Canon, Inc.
11.6 Lifelines Neuro Company, LLC
11.7 Natus Medical Incorporated
11.8 F. Hoffmann-La Roche AG
11.9 FUJIFILM Holdings Corporation
11.10 Mitsar Co., Ltd.
11.11 Advanced Brain Monitoring, Inc.
11.12 Thermo Fisher Scientific, Inc.
11.13 Bio-Rad Laboratories
11.14 QIAGEN N.V.
11.15 Nihon Kohden Corporation
11.16 Other Companies
11.16.1 ANT Neuro
11.16.2 Fonar Corporation
11.16.3 Fujirebio (A Part of Miraca Group)
11.16.4 DRG Instruments GmbH
11.16.5 Tecan Trading AG
*Business Overview, Products Offered, Recent Developments, MnM View Might Not be Captured in Case of Unlisted Companies.
12 Appendix (Page No. – 213)
12.1 Discussion Guide
12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
12.3 Available Customizations
12.4 Related Reports
12.5 Author Details
